New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)
.
Saved in:
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2016-09-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Online Access: | https://www.rpcardio.online/jour/article/view/1319 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|